Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fructosamine Reference Range Established for Brazil

By LabMedica International staff writers
Posted on 14 Jan 2019
Traditional markers used in diabetes diagnosis and monitoring include fasting plasma glucose (FPG), two-hour plasma glucose (2-hPG) measured during the oral glucose tolerance test (OGTT), and glycated hemoglobin (HbA1c) levels.

The fructosamine test is used in the monitoring of diabetes mellitus, particularly in cases with restrictions on the use of glycated hemoglobin, mainly in the setting of altered red blood cell lifespan and interference by hemoglobin variants. More...
It could also provide additional information on shorter-term glycemic control.

Scientists at the Federal University of Minas Gerais, (Belo Horizonte, Brazil) collected blood samples from 2,288, that were part of a comprehensive study and available for fructosamine testing. The team excluded from the study individuals with a previous history of diabetes (n = 161), with FPG ≥ 5.6 mmol/L (100 mg/dL) and/or 2-hPG ≥ 7.8 mmol/L (140 mg/dL) and/or HbA1c ≥ 38.8 mmol/mol, (5.7%). They also excluded individuals with microalbuminuria ≥ 20 μg/min and creatinine> 114.9 µmol/L (1.3 mg/dL).

Samples were collected after a 12-h fasting period. The OGTT was conducted in all participants included in the present study. Samples were stored at −80 °C. Serum fructosamine levels were determined by the colorimetric nitroblue tetrazolium method in an AU 5800 automatic analyzer. The scientists proposed that the reference interval should be 186 to 248 μmol/L for women and 196 to 269 μmol/L for men. Fructosamine levels were higher in men than in women and in the non-white population and had a negative correlation with the body mass index.

The authors concluded that their study represents the first effort to establish a reference range for fructosamine levels in the Brazilian population. The report, which used the ELSA-Brazil baseline as a source of data, might contribute to future work on the diagnosis and monitoring of diabetes mellitus (DM), especially in situations when HbA1c and OGTT cannot be used. The study was published in the January 2019 issue of the journal Practical Laboratory Medicine.

Related Links:
Federal University of Minas Gerais


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Clinical Informatics Platform
CLARION™
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The portable platform could address diagnostic gaps for tuberculosis testing in clinics without access to advanced laboratory infrastructure (photo credit: Shutterstock)

Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes

Despite decades of effective drug regimens, tuberculosis remains the leading cause of death from an infectious disease, driven in part by limited access to accurate, rapid testing. Conventional diagnostics... Read more

Pathology

view channel
Image: The researchers derived a gene-based signature and a blood test to help identify this high-risk subgroup (photo credit: Shutterstock)

New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease

Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.